Neurocrine Biosciences, Inc.
NBIXHealthcareNASDAQDrug Manufacturers - Specialty & Generic
Scan Results
Daily timeframeNeurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. Valued at $14.51B, NBIX is a large-cap name in its sector. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.
Market Cap
$14.51B
Beta
0.40
P/E (TTM)
20.92
P/E (Fwd)
11.92
EPS (TTM)
$6.82
EPS (Fwd)
$11.97
ROE
22.1%
ROA
11.7%
Cash
$389.8M
Total Debt
$461.6M
Free CF
$638.2M
52W Change
-4.2%
Annual Financials
Cash vs Debt
Where NBIX stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, NBIX finished 10.43% below its 150-day moving average ($151.52) and 7.71% below its 200-day moving average ($147.04). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NBIX overbought or oversold?
At the October 19, 2026 close, NBIX's RSI(14) was 41.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $389.8M in cash, though total debt stands at $461.6M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $638.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 22.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 11.7% further supports the picture of efficient asset utilization. Revenue has grown from $1.49B (2022) to $2.86B (2025), reflecting a 92% increase over the period.
With a beta below 0.7, Neurocrine Biosciences, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Neurocrine Biosciences, Inc.'s trajectory.